LYTGOBI (futibatinib), used for cholangiocarcinoma, has a price influenced by multiple factors.
High R&D costs are a major factor. Developing this FGFR inhibitor involves extensive research, clinical trials, and significant investment. Patent protection gives the manufacturer exclusive rights, allowing for higher pricing without generic competition.
Production costs matter too. Specialized manufacturing processes and strict quality control add to expenses. Market demand also impacts the price. As it targets a specific patient group with FGFR2 mutations, the relatively small patient pool affects the supply - demand balance.

